According to CAIVD statistics, at present, the main in vitro diagnostic listed enterprises (in vitro diagnostic business revenue accounted for more than 50%) total: 62. They cover three segments: production, service (third-party medical testing ICL) and distribution (trade). Among them, 46 are production enterprises (including 2 enterprises mainly engaged in in vitro diagnostic laboratory consumables), 11 are service enterprises and 5 are distribution enterprises. Since 2004, the main in vitro diagnostics listed the first stock Kehua Biological to the latest listed Kangwei Century are witnessing the development of China's in vitro diagnostic industry, I summarized the information of the main in vitro diagnostic enterprises in 2022 third quarter reports for the benefit of readers.

 

Chinese listed companies mainly engaged in IVD business 2022 third quarter operating income analysis

 

 

Note: The third quarterly reports of New Horizon Health, Kehua Bio and Cowin Biotech were not disclosed.

  

The semi-annual reports of 2022 main in vitro diagnostic enterprises totaled CNY44.608 billion of operating revenue, of which CNY24.024 billion, or 53.86% of the total, was from production-oriented enterprises. Service enterprises had operating revenues of CNY13.165 billion, accounting for 29.51% of the total. Circulation-type enterprises operating income of CNY7.419 billion, accounting for 16.63% of the total. According to the previous article "58 IVD companies' revenue exceeded CNY120 billion in the first half of the year! 2022 half-year revenue has reached CNY126.782 billion, plus the current three quarters total operating income of CNY44.608 billion, 2022 main in vitro diagnostic enterprises in the first three quarters total operating income CNY171.39 billion, we believe that soon, the upcoming 2022 main in vitro diagnostic enterprises annual report operating income, total operating income can steadily exceed CNY200 billion mark!

 

Mainly in vitro diagnostic business production-oriented companies in the third quarter of 2022 revenue

 

 

Note: The third quarterly reports of Kindstar Globalgene Technology and Genetron Health were not disclosed.

 

The main IVD business manufacturing company Daan Genetics topped the list with revenue of CNY2.66 billion. Daan Genetics is not only the pioneer of nucleic acid testing technology in China, but also an important contributor to China's nucleic acid testing technology products becoming products representing the international cutting-edge technology level. The company focuses on the development and application of fluorescent PCR diagnostic reagents, and has undertaken more than 30 national and provincial key research projects, and the research results have won various awards such as the National Science and Technology Progress Award and the National Invention Gold Medal. After nearly 30 years of cultivation, the company has completed the whole industrial chain of nucleic acid testing technology, including R&D and production, core raw materials, quality control products, instrument development and production, and testing services. The company, as the Ministry of Health Pharmaceutical Biological Engineering Technology Research Center, National Clinical Molecular Diagnostics National Local Joint Engineering Laboratory, Guangzhou Molecular Diagnostics Technology Research Center, National Certified Enterprise Technology Center and Guangzhou Antibody Technology Research Center, has a national enterprise intellectual property rights pilot unit, and won the title of National Key New Product and Guangdong Key New Product. Up to now, it has applied for more than 200 invention patents, including 78 granted invention patents, covering various aspects such as prenatal screening, newborn screening, hormone testing, pathology diagnosis, public health surveillance, real-time diagnosis of infectious diseases, tumor gene mutation detection, and individualized medication guidance. Daan Gene is a leading molecular diagnostic company. During the epidemic, the company developed the nucleic acid test kit for the new coronavirus, which was the first to be released and developed for the new coronavirus nucleic acid test reagent in China.

 

Mainly IVD business service-based company revenue in the third quarter of 2022

 

 

Note: The third quarterly reports of New Horizon Health, Kindstar Globalgene Technology, Kehua Bio, Cowin Biotech, Kang Sheng Global, Huajian Medical, and Genetron Health were not disclosed.

 

Dian Diagnostics, a service company mainly engaged in IVD business, topped the list with revenue of CNY4.876 billion. Dian Diagnostics Technology Group Co. The company was founded in 1996 and went public in July 2011 (stock code: 300244). With the mission of "Let's share the health of the nation equally", the company has actively laid out the industrial ecological chain, and its business covers medical diagnostic services, diagnostic technology research and development, diagnostic product production and marketing, CRO, forensic identification, health management, cold chain logistics and other fields.

 

Mainly in vitro diagnostic business distribution-oriented companies 2022 third quarter revenue

 

Note: The third quarterly report of Huaji Medical was not disclosed.

 

With revenue of CNY3.601 billion, distribution-oriented company mainly engaged in IVD business, Yestar Healthcare, one of the leading high-margin medical consumables and equipment companies in China, topped the list. Based in the booming medical industry in China, the Group's core business focuses on high-margin medical consumables and equipment, namely medical imaging products and IVD products. Since its establishment, the Group has built up an extensive sales network in China backed by a sound and systematic management system, and has won the trust of internationally renowned manufacturers such as Fujifilm, Roche Diagnostics, Beedie and Thermo Fisher. Currently, the Group is the exclusive manufacturer of medical films for Fujifilm in China and one of the largest distributors of medical in-vitro diagnostic products for Roche Diagnostics in China. The Group is also the sole manufacturer and exclusive distributor of Fujifilm's color photo paper and industrial imaging products in the PRC. In addition, the Group manufactures and sells medical dental films under its own brand "Yes! Star Medical will continue to look for potential M&A opportunities and strategic partnerships with industry giants to strengthen its strong position in the medical industry. In the foreseeable future, the Group will further expand its market share in the high-margin medical consumables and equipment products industry in China.

 

Of course, in addition to the main in vitro diagnostic business listed companies, companies like Mindray Medical, Wantai Biological, Fosun Pharmaceutical, Lepu Medical, Sino Biological, Weigao, Kingsray Biological, Huxin Instruments, Haier Biological, Zhongyuan Concord, Xinhua Medical, Uninvest, Bepsix, Kangtai Medical, Tianrui Instruments, etc. have good performance.

 

There are also many enterprises applying for listing at the moment. Shanghai Kaishi Biotechnology Co., Yisheng Biotechnology (Shanghai) Co., Intco Xinchuang (Xiamen) Technology Co., Xiamen Zhishan Biotechnology Co. Ltd.

 

Looking forward to the annual summary of annual operating revenue of main in vitro diagnostic enterprises in 2022, breaking the 200 billion mark. At the moment when epidemic prevention and control policies around the world are showing changes, we need to encourage innovation, support the spirit of stimulating IVD companies to take the initiative to innovate, and actively provide more adequate and effective support for each link in the industry chain. The road to innovation is inherently rugged, and we doubly need tolerance and understanding. In the long history of the development and progress of laboratory medicine, in the process of prevention, diagnosis and disease treatment, the important role of laboratory medicine and in vitro diagnostic industry is irreplaceable by any discipline. We should firmly believe that Chinese IVD people will have the confidence and ability to walk with the people of the country, to walk with those who are going against the trend and to be of one mind with those who are fighting the epidemic.

 

Through this big test of the epidemic, the development progress and comprehensive strength of China's in vitro diagnostic industry will be greatly promoted and boosted. We firmly believe that the fundamentals of China's in vitro diagnostic industry have not changed and will not change in the near future, and a strong health industry cluster from "in China for China to in China for the world" will definitely stand in the east of the world.